



Louisiana Board of Pharmacy

3388 Brentwood Drive
Baton Rouge, Louisiana 70809-1700
Telephone 225.925.6496 ~ E-mail: info@pharmacy.la.gov



NOTICE IS HEREBY GIVEN that a meeting of the Board has been ordered and called for **9:00 a.m. on Wednesday, February 19, 2025** at the Board office, for the purpose to wit:

A G E N D A

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

Revised 2-17-2025 (Rev1)

1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items & Adoption of Agenda
5. Consideration of Draft Minutes from Previous Meeting: November 20, 2024
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
9. Special Orders of the Day
10. Committee Reports
 - A. Finance – Mr. Soileau
 - B. Application Review – Ms. Melancon
 - C. Reciprocity – Mr. Mannino
 - (1) List of Pharmacists Licensed by Reciprocity
 - D. Violation – Mr. Indovina
 - (1) Consideration of Proposed Voluntary Consent Agreements
 - a. Case No. 24-0338 ~ PST.018113 – Paula Dupre Michot Cannon
 - b. Case No. 24-0332 ~ PHY.002125 – Louisiana Walgreen Pharmacy, Inc. *d/b/a* Walgreen Pharmacy #15199
 - c. Place Holder – Pending Consent Agreement
 - d. Place Holder – Pending Consent Agreement
 - e. Case No. 24-0329 ~ PST.015203 – Vernance Patrice Collins-Burnett +
 - f. Case No. 24-0330 ~ PST.018760 – Darvis Keon Harvey
 - E. Impairment – Ms. Hall ([Committee Agenda](#))
 - (1) Consideration of Committee Recommendations re Applications
 - F. Reinstatement – Dr. Strong ([Committee Agenda](#))
 - (1) Consideration of Committee Recommendations re Applications
 - (2) Reinstatements by Board Policy Since Last Meeting
 - G. Tripartite – Mr. Resweber

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a person, (2) strategy sessions or negotiations with respect to litigation, (3) discussions regarding the report, development, or course of action regarding security personnel, plans, or devices, including discussions concerning cybersecurity plans, financial security procedures, and assessment and implementation of any such plans or procedures, (4) investigative proceedings regarding allegations of misconduct, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTE: To request a disability accommodation, please contact Joe Fontenot, Executive Director, at 225.925.6496 or email at jfontenot@pharmacy.la.gov

Louisiana Board of Pharmacy
Board Meeting Agenda – February 19, 2025

Page 2

- H. Regulation Revision – Dr. Cloud
 - (1) Legislative Proposal 2025-B ~ CDS Schedules Update ([Draft #1](#))
 - (2) Regulatory Project 2025-03 ~ Pharmacy Technician Certificate Qualifications ([Draft #2](#))
 - (3) Regulatory Proposal 2025-B ~ Nonresident Pharmacy ([Draft #1](#))
 - (4) Regulatory Proposal 2025-C ~ Practitioner CDS License ([Draft #1](#))
 - (5) Rule Review – LAC 46:LIIL.101-525 Pursuant to Act 192 (2024-RS)
 - (6) Proposed Pilot Project – Remote Processing Services – Final Product Verification
 - I. Executive Committee – Mr. McKay ([Committee Agenda](#))
 - (1) Consideration of Proposed Policy & Procedure Manual (PPM) Revisions
 - a. Proposed Revision PPM.II.B.1.h ~ Telephone Procedures
 - b. Proposed Revision PPM.II.B.3.b ~ Employment
 - c. Proposed Revision PPM.II.B.3.f ~ Leave Establishment & Records
 - d. Proposed Revision PPM.II.B.4.a ~ Employment Benefits
 - e. Proposed Revision PPM.II.B.4.e ~ Annual & Sick Leave
 - f. Proposed Revision PPM.II.C.5.a ~ Property
 - g. Proposed Revision PPM.II.D.1.a ~ Computers
 - h. Proposed Revision PPM.II.D.2.a ~ Record Retention Schedule, Pages 5 & 7 of 8
 - i. Proposed Revision PPM.IV.B.2 ~ Service Reviews
 - (2) Consideration of Proposed Loss Prevention Manual (LPM) Revisions
 - a. Proposed Revision LPM.I.Q ~ Transitional Return to Work Plan
 - (3) Notice of *Exceptions Report*
11. Staff Reports
- A. General Counsel – Mr. Finalet
 - (1) Consideration of Proposed Voluntary Consent Agreements & Surrenders
 - a. Case No. 24-0349 ~ CPT.017867 – Jasmin Selene Dangerfield
 - b. Case No. 24-0371 ~ PHY.008616 – MixMyRx Ventures, LLC d/b/a MixMyRx
 - c. Case No. 24-0378 ~ CPT.016726 – D'Shay Nicole Watson
 - d. Case No. 24-0352 ~ PST.022312 – Pankajkumar Damodar Patel
 - e. Case No. 24-0392 ~ PHY.007430 – Pharmacy Partners of Texas, LLC d/b/a Advanced Pharmacy
 - f. Case No. 25-0001 ~ PHY.008069 – Hill Derm Pharmacy, LLC
 - g. Case No. 24-0397 ~ PST.016005 – Corey Allen Sorrel
 - h. Case No. 25-0002 ~ PST.024704 – Evan Keylon Cleaver
 - i. Case No. 24-0372 ~ PHY.008475 – Hamilton Pharmacy and Medical Company Inc. d/b/a Alexander's Twin Pharmacy
 - B. Executive Director's Report – Mr. Fontenot
 - (1) Prescription Monitoring Program (PMP) – [Quarterly Report](#)
 - (2) Consideration of *Requests for Exemptions* from PMP Reporting
 - (3) [NAPLEX Passing Rates](#) for 2022-2024 Graduates

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a person, (2) strategy sessions or negotiations with respect to litigation, (3) discussions regarding the report, development, or course of action regarding security personnel, plans, or devices, including discussions concerning cybersecurity plans, financial security procedures, and assessment and implementation of any such plans or procedures, (4) investigative proceedings regarding allegations of misconduct, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTE: To request a disability accommodation, please contact Joe Fontenot, Executive Director, at 225.925.6496 or email at jfontenot@pharmacy.la.gov

Louisiana Board of Pharmacy
Board Meeting Agenda – February 19, 2025

Page 3

(4) [MPJE Passing Rates](#) for 2022-2024 Graduates

12. New Agenda Items Added During Meeting

13. Announcements

14. Adjourn

NOTE: Pursuant to the Open Meetings Law at R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a person, (2) strategy sessions or negotiations with respect to litigation, (3) discussions regarding the report, development, or course of action regarding security personnel, plans, or devices, including discussions concerning cybersecurity plans, financial security procedures, and assessment and implementation of any such plans or procedures, (4) investigative proceedings regarding allegations of misconduct, or other purposes itemized at La. R.S. 42:17.

NOTE: In compliance with Act 256 of the 2019 Louisiana Legislature, the Board gives public notice that any information submitted to the Board may become public record unless specifically exempted by the Public Records Law, R.S. 44:1 *et seq.*

NOTE: To request a disability accommodation, please contact Joe Fontenot, Executive Director, at 225.925.6496 or email at jfontenot@pharmacy.la.gov